Receptor News and Research

RSS

UCLA researchers uncover potential to restore lost memories in patients with early Alzheimer's

New UCLA research indicates that lost memories can be restored. The findings offer some hope for patients in the early stages of Alzheimer's disease.

23 Dec 2014

Eating habits and brain chemistry: an interview with Dr Kevin Hall

Several times every day, we choose when, where, what, with whom, and how much to eat. Many of these eating decisions have become automatic and don’t require cognitive effort.

22 Dec 2014

Mexican study shows mobility can be restored in patients with Parkinson's disease

Mexican scientists demonstrated experimentally, with adult rats, that mobility can be restored in patients with Parkinson's disease, the major degenerative disease of the motor system worldwide.

22 Dec 2014

Chromosome X microduplications implicated in infancy-onset gigantism

Researchers report that heritable microduplications on chromosome Xq26.3 may underlie a “striking” form of gigantism with onset in late infancy, and reveal a candidate culprit gene.

22 Dec 2014

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes.

From Novo Nordisk 22 Dec 2014

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

A common polymorphism - a variation in a person's DNA sequence that is found with regularity in the general population - can lead to a chain of events that dictates how a tumor will progress in certain types of cancer, including a form of breast cancer as well as ovarian cancer, according to new research from The Wistar Institute that was published online by the journal Cancer Cell.

19 Dec 2014

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests.

19 Dec 2014

Gene variations predispose mestizo Mexican population to develop severe form of COPD

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases, found that the mestizo Mexican population has a number of variations in certain genes that predispose them to develop the most severe form of chronic obstructive pulmonary disease (COPD).

19 Dec 2014

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Stanton McHardy, associate professor of chemistry and director of the Center for Innovative Drug Discovery in The University of Texas at San Antonio College of Sciences, is partnering on a $1.9 million award to develop next-generation breast cancer treatment drugs.

19 Dec 2014

Two orphan receptor proteins exert fatal double whammy effect against glioblastoma cells

Two related proteins exert a lethal double whammy effect against glioblastoma cells when activated with a small molecule, say researchers at Georgetown Lombardi Comprehensive Cancer Center.

18 Dec 2014

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV

17 Dec 2014

Researchers identify 53 existing drugs that may block Ebola virus from entering human cells

Researchers found 53 existing drugs that may keep the Ebola virus from entering human cells, a key step in the process of infection, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and the National Institutes of Health, and published today in the Nature Press journal Emerging Microbes and Infections.

17 Dec 2014

RCC renal function independent of axitinib-induced proteinuria

Treatment with the vascular endothelial growth factor receptor inhibitor axitinib does not adversely affect renal function in patients with metastatic renal cell carcinoma even in the presence of proteinuria, a Japanese study indicates.

17 Dec 2014

Investigational drug increases PFS in patients with advanced breast cancer

In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.

17 Dec 2014

Researchers examining new antioxidant-based therapeutic approaches to hypertension

High blood pressure affects more than 70 million Americans and is a major risk factor for stroke, heart failure and other renal and cardiovascular diseases. Two University of Houston College of Pharmacy researchers are examining the role of intrinsic antioxidant pathways in mitigating hypertension.

17 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.

16 Dec 2014

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, today announce the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

16 Dec 2014

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.

16 Dec 2014

Receptor News and Research

UCLA researchers uncover potential to restore lost memories in patients with early Alzheimer's

Eating habits and brain chemistry: an interview with Dr Kevin Hall

Mexican study shows mobility can be restored in patients with Parkinson's disease

Chromosome X microduplications implicated in infancy-onset gigantism

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Gene variations predispose mestizo Mexican population to develop severe form of COPD

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Two orphan receptor proteins exert fatal double whammy effect against glioblastoma cells

Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify 53 existing drugs that may block Ebola virus from entering human cells

RCC renal function independent of axitinib-induced proteinuria

Investigational drug increases PFS in patients with advanced breast cancer

Researchers examining new antioxidant-based therapeutic approaches to hypertension

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News